CaliciX™ Max is a high-strength systemic antiviral capsule formulated for cats suffering from severe, refractory, or high-viral-load feline calicivirus (FCV) disease, where standard-dose therapy may be insufficient.

CaliciX™ Max contains 30 mg of EIDD-1931 per capsule, allowing veterinarians to achieve higher systemic antiviral exposure with fewer capsules. It is intended for step-up therapy in advanced or poorly responsive FCV cases.

CaliciX™ Max may be considered under veterinary supervision when a cat has:

• Severe oral or oropharyngeal disease

• Refractory FCGS or post-extraction stomatitis

• High systemic viral burden

• Poor response to conventional dosing

• Larger body weight requiring higher per-dose exposure

CaliciX™ Max is formulated to support cats with severe FCV-associated disease, including:

• Severe feline chronic gingivostomatitis (FCGS)

• Caudal stomatitis with extensive inflammation

• Deep lingual ulceration (viral glossitis)

• Multifocal oral ulceration

• Virulent systemic feline calicivirus (VS-FCV)

In cases of suspected or confirmed virulent systemic FCV, higher systemic antiviral exposure may be required.

CaliciX™ Max is designed for veterinarian-directed use in such severe presentations, alongside intensive supportive care.

No. CaliciX™ Max is not an antibiotic. It is a direct-acting antiviral designed to suppress viral replication. Antibiotics may still be used separately to manage secondary bacterial infections when indicated.

EIDD-1931 interferes with viral RNA replication by inducing lethal mutagenesis in RNA viruses. This mechanism:

• Does not rely on viral proteases

• Has a high genetic barrier to resistance

• Works independently of host immune status

Some cats with chronic or refractory FCV may require extended antiviral management. Treatment duration and monitoring should always be determined by a licensed veterinarian.

No. CaliciX™ Max is intended to be part of a comprehensive veterinary treatment plan, which may include dental procedures, pain control, nutritional support, and other therapies as needed.

CaliciX™ Max contains EIDD-1931, the active antiviral metabolite of molnupiravir, but is formulated specifically for veterinary use in cats.

CaliciX™ Max is intended for veterinary-supervised use only. It may not be suitable for:

• Pregnant or breeding cats

• Cats with significant hepatic or renal disease Veterinary assessment is required before use.

The 30 mg strength allows veterinarians to:

• Achieve higher antiviral exposure

• Reduce capsule burden in large or severe cases

• Improve dosing accuracy and compliance

This makes it suitable for advanced or high-risk FCV disease.

Yes. CaliciX™ Max is intended for off-label veterinary use under professional supervision, with informed owner consent.